191 related articles for article (PubMed ID: 34204722)
1. Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families.
Fonfria M; de Juan Jiménez I; Tena I; Chirivella I; Richart-Aznar P; Segura A; Sánchez-Heras AB; Martinez-Dueñas E
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34204722
[TBL] [Abstract][Full Text] [Related]
2. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
4. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
5. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
[TBL] [Abstract][Full Text] [Related]
6. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
Front Oncol; 2022; 12():976959. PubMed ID: 36119527
[TBL] [Abstract][Full Text] [Related]
7. Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer.
Turchiano A; Piglionica M; Martino S; Bagnulo R; Garganese A; De Luisi A; Chirulli S; Iacoviello M; Stasi M; Tabaku O; Meneleo E; Capurso M; Crocetta S; Lattarulo S; Krylovska Y; Lastella P; Forleo C; Stella A; Bukvic N; Simone C; Resta N
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628581
[TBL] [Abstract][Full Text] [Related]
8. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
[TBL] [Abstract][Full Text] [Related]
9. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
10. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond
Fanale D; Incorvaia L; Filorizzo C; Bono M; Fiorino A; Calò V; Brando C; Corsini LR; Barraco N; Badalamenti G; Russo A; Bazan V
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32854451
[TBL] [Abstract][Full Text] [Related]
11. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
12. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
[TBL] [Abstract][Full Text] [Related]
13. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
[TBL] [Abstract][Full Text] [Related]
14. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.
Bucalo A; Conti G; Valentini V; Capalbo C; Bruselles A; Tartaglia M; Bonanni B; Calistri D; Coppa A; Cortesi L; Giannini G; Gismondi V; Manoukian S; Manzella L; Montagna M; Peterlongo P; Radice P; Russo A; Tibiletti MG; Turchetti D; Viel A; Zanna I; Palli D; Silvestri V; Ottini L
Eur J Cancer; 2023 Jul; 188():183-191. PubMed ID: 37262986
[TBL] [Abstract][Full Text] [Related]
15. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
[TBL] [Abstract][Full Text] [Related]
16. The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
Daly MB; Rosenthal E; Cummings S; Bernhisel R; Kidd J; Hughes E; Gutin A; Meek S; Slavin TP; Kurian AW
Breast Cancer Res Treat; 2023 Jun; 199(3):617-626. PubMed ID: 37084156
[TBL] [Abstract][Full Text] [Related]
17. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
19. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
[TBL] [Abstract][Full Text] [Related]
20. The results of multigene panel sequencing in Slovak HBOC families.
Konecny M; Kosova K; Tilandyova P; Wachsmannova L; Baldovic M; Krajcovic J; Patlevicova A; Markus J; Ciernikova S
Neoplasma; 2021 May; 68(3):652-664. PubMed ID: 33724863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]